- Home
- ABVC vs SNTI Comparison
ABVC vs SNTI Comparison
Compare ABVC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- SNTI
- Stock Information
- Founded
- ABVC 2015
- SNTI 2016
- Country
- ABVC United States
- SNTI United States
- Employees
- ABVC N/A
- SNTI N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- SNTI Health Care
- Exchange
- ABVC Nasdaq
- SNTI Nasdaq
- Market Cap
- ABVC 16.7M
- SNTI 17.8M
- IPO Year
- ABVC N/A
- SNTI N/A
- Fundamental
- Price
- ABVC $0.93
- SNTI $3.05
- Analyst Decision
- ABVC
- SNTI Strong Buy
- Analyst Count
- ABVC 0
- SNTI 1
- Target Price
- ABVC N/A
- SNTI $12.00
- AVG Volume (30 Days)
- ABVC 282.7K
- SNTI 25.4K
- Earning Date
- ABVC 05-16-2025
- SNTI 05-08-2025
- Dividend Yield
- ABVC N/A
- SNTI N/A
- EPS Growth
- ABVC N/A
- SNTI N/A
- EPS
- ABVC N/A
- SNTI N/A
- Revenue
- ABVC $509,788.00
- SNTI N/A
- Revenue This Year
- ABVC N/A
- SNTI N/A
- Revenue Next Year
- ABVC N/A
- SNTI N/A
- P/E Ratio
- ABVC N/A
- SNTI N/A
- Revenue Growth
- ABVC N/A
- SNTI N/A
- 52 Week Low
- ABVC $0.40
- SNTI $1.52
- 52 Week High
- ABVC $1.73
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- ABVC 68.26
- SNTI 45.76
- Support Level
- ABVC $0.65
- SNTI $3.02
- Resistance Level
- ABVC $1.40
- SNTI $3.56
- Average True Range (ATR)
- ABVC 0.10
- SNTI 0.31
- MACD
- ABVC 0.05
- SNTI -0.01
- Stochastic Oscillator
- ABVC 62.03
- SNTI 31.25
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.